Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,444 | 252 | 2,180 |
| Samples | 851 | 143 | 703 |
| Peptides | 748 | 107 | 664 |
Function
MYPN · Myopalladin
Striated muscle in vertebrates comprises large proteins which must be organized properly to contract efficiently. Z-lines in striated muscle are a sign of this organization, representing the ends of actin thin filaments, titin, nebulin or nebulette and accessory proteins required for structure and function. This gene encodes a protein which interacts with nebulin in skeletal muscle or nebulette in cardiac muscle and alpha-actinin. In addition, this gene product can interact with a protein with the I-band indicating it has a regulatory as well as structural function. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2011].
Isoforms & Proteins
5 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000358913 | Q86TC9 | 1,044 | 644 |
| ENST00000354393 | Q86TC9-2 | 825 | 505 |
| ENST00000373675 | A0A804CFL5* | 267 | 208 |
| ENST00000540630 | A0A8J9ASZ5* | 233 | 181 |
| ENST00000613327 | Q86TC9 | 75 | 35 |
Gene Properties
Recurrent Mutations
All 644 amino-acid changes on canonical ENST00000358913 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MYPN · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MYPN – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Gastrointestinal Stromal Tumour | 0/0 0% | 34/133 26% |
| Oral Cavity Carcinoma | 5/54 9% | 0/0 0% |
| Endometrial Carcinoma | 6/42 14% | 38/612 6% |
| Melanoma | 15/210 7% | 98/1899 5% |
| Non-Small Cell Lung Carcinoma | 23/304 8% | 63/1390 5% |
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 33/810 4% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Other Solid Cancers | 4/94 4% | 60/1515 4% |
| Colorectal Carcinoma | 18/143 13% | 76/3239 2% |
| Neuroendocrine Tumour | 13/154 8% | 7/577 1% |
| Cervical Carcinoma | 4/35 11% | 7/422 2% |
| Bladder Carcinoma | 5/58 9% | 19/956 2% |
| Small Cell Lung Carcinoma | 2/9 22% | 15/752 2% |
| Gastric Carcinoma | 5/74 7% | 34/1809 2% |
| Adrenocortical Carcinoma | 2/3 67% | 0/112 0% |
| Head and Neck Carcinoma | 2/85 2% | 26/1574 2% |
| Esophageal Squamous Cell Carcinoma | 3/51 6% | 38/2550 1% |
| Germ Cell Tumour | 1/25 4% | 2/169 1% |
| Plasma Cell Myeloma | 0/44 0% | 5/305 2% |
| Non-Cancerous | 0/104 0% | 12/830 1% |
| Hepatocellular Carcinoma | 2/46 4% | 25/2210 1% |
| Acute Myeloid Leukemia | 1/90 1% | 0/0 0% |
| Biliary Tract Carcinoma | 1/54 2% | 8/950 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| B-Cell Non-Hodgkins Lymphoma | 3/88 3% | 18/2534 1% |
| Esophageal Carcinoma | 0/23 0% | 6/769 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Medulloblastoma | 0/0 0% | 3/450 1% |
| Pancreatic Carcinoma | 4/89 4% | 7/1611 0% |
Mutation Distribution
Where MYPN is mutated · all tissues, split by cell line vs tissue
How many mutations in MYPN were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,444 mutations in MYPN
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|